You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy

    SBC: Regulonix            Topic: 101

    Summary Abstract Chemotherapy induced peripheral neuropathyCIPNis detected inof cancer patients during all phases of cancerSensory symptoms in the hands and or feettypically in astocking glovepatternare commonand manifested as painnumbnessand or tinglingCIPN can result in chemotherapy dose reduction or discontinuationand can also have long term effects on the quality of lifeThe course of CIPN can ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a Nutraceutical Product against Ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Glioblastoma multiforme therapy via telomerase reverse transcriptase (hTERT) down-regulation. Molecular chaperones redirect quadruplex folding to reverse the effect of hTERT gene promoter mutations.

    SBC: Reglagene, LLC            Topic: 106

    Project Summary Overexpression of hTERT is a hallmark of cancer and is associated with oncogenesistumor maintenanceand resistance to conventional chemotherapyElongated telomeres at the ends of chromosomes are a hallmark for cancer in the early stage of tumorigenesis and are associated with genetic instabilityAs a consequencesuppressed telomerase in normal cells is highly activated to immortalize t ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Biologically Targeted Vaccine for Chikungunya

    SBC: PRECISION VIROLOGICS INC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)

    SBC: AQUALUNG THERAPEUTICS CORP.            Topic: NHLBI

    PROJECT SUMMARYMortality rates in intensive care unitsICUsare unacceptably high and are directly related to the duration of mechanical ventilation that is required to support patients with respiratory failureFor exampleacute respiratory distress syndromeARDSis a vexing acute inflammatory lung disease requiring mechanical ventilatory support as the result of severe hypoxemia and respiratory failure ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a bioconjugate vaccine against Group B Streptococcus

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Streptococcus agalactiaecommonly referred to as Group B StreptococcusGBSis a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in both pregnant and non pregnant adultsGBS neonatal disease manifests as early onsetdefined as disease within the first six days after birthor late onsetdefined as disease occurring after the first week of li ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Use of mimotope vaccine technology to develop vaccines against bacterial pathogens

    SBC: ZenVax LLC            Topic: NIAID

    ABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients

    SBC: AQUALUNG THERAPEUTICS CORP.            Topic: NHLBI

    PROJECT SUMMARYAcute Respiratory Distress SyndromeARDSis a devastatingly intense lung inflammatory disorder that annually afflicts more thanmillion individuals world widecases year in the U Swith an unacceptable mortality rate ofSubstantial clinical and biological heterogeneity within ARDS phenotypes has greatly impeded therapeutic developments to reduce mortalityAll therapies currently employed i ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractThere are a number of rare neurodegenerative diseasesincluding Amyotrophic Lateral SclerosisALSand Huntington s DiseaseHDfor which there is no available or effective therapy and which lead to significant morbidity and mortality ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy

    SBC: Medical Guidance Systems LLC            Topic: 102

    Abstract The proposed drug development will result in the design and development of a ligand targeted liposomeLTLthat will aid in the targeted delivery of therapeutics to patients with Non Small Cell Lung CancerNSCLCWe propose an innovative active targeting strategy and our technology exploits the stress response that occurs within the cancer cells following exposure to ionizing radiationThis lipo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government